Decision Diagnostics Corp (DECN)

[pumper_stumper]

PR #5 Happy 2 Year Anniversary to Keith and his big lie! ( days late on this one, sorry.. hard to keep up with all the pink sheet fun! lol)

A day since the last PR and yes, again, another raise to the "forecast". Once again, anyone with half a brain should see by this alone that this is a scam!!!!

https://www.accesswire.com/581057/DECNS-GenViroTM-Corona-Virus-Swift-Kit-Now-to-Be-Additionally-Offered-to-Commercial-Labs-and-Religious-Groups-as-12-Month-Forecast-is-Raised-to-525MM

DECN'S GenViro!(TM) Corona Virus "Swift" Kit, Now to Be Additionally Offered to Commercial Labs and Religious Groups as 12 Month Forecast is Raised to 525MM
Tuesday, March 17, 2020

RESPONSE FROM MEDICAL/HEALTHCARE ENTITIES & WHOLESALERS HAS BEEN CRUSHING AS GROUPS QUEUE UP FOR COVID-19 "SWIFT" KIT WHILE WE AWAIT FDA EMERGENCY APPROVAL

LOS ANGELES, CA / ACCESSWIRE / March 17, 2020 /

Today, in this second of four updates about our GenViro™ Swift" kit for the testing of COVID-19, we will focus on our expected roll-out. We are happy to inform all interested parties that we have raised our 12-month forecast to 525 million kits. We have also added commercial laboratories, those labs with remote blood drawing stations (an estimated 27,000 nationwide), and religious groups to those entities that will receive the first kits manufactured post FDA Emergency Approval. These additional groups join chain pharmacies and grocers with pharmacies, clinics, home health service providers, and medical group practices as the first to receive our GenViro™ kits.

Keith Berman, CEO of DECN commented, "Our first roll-out of 150,000 GenViro™ kits in the US and Canada will be paired with a roll-out of 100,000 GenViro™ kits in the EU. The first kits manufactured will be provided, free of charge or at a nominal fee, to professional entities. These groups include chain pharmacies and grocery store pharmacies, commercial laboratories with remote blood drawing stations, churches and other places of worship, as well as clinics and long term care facilities. Ultimately, GenViro™ will be sold directly to consumers, as our roll-out progresses."

Mr. Berman continued, "Over the weekend, and after receiving a plan from our technical and R&D director, we decided to take the next step with GenViro™and further refine its use for hospitals. While we have not yet forecast sales to hospitals, and while most of the lesser but competitive products are directed toward hospital uses, we nonetheless believe that hospitals will be a large future source of revenues. When we complete this round of information releases, our fourth release will include a hospital forecast.

Mr. Berman concluded, "As you might imagine with a product announcement of such importance, we have been contacted by a number of potential partners for our kit. (editor note: keep in mind ZERO is a number!) To date we have discussed our GenViro™ product with a big box pharmacy chain, a master medical products distribution company, a large commercial lab, and a home health organization. All of these entities want the kits and we intend to write their business.

We are not resting our laurels with our GenViro development. Later product entries will be test methods for Polio, Ebola (Marburg), Bird Flu, and SARS. The cost of our test kits will be sold in a price range of $4.95 to $7.95 per use. The Coronavirus kit will wholesale $6.95. Each kit sold will carry enough diagnostic for two tests, a primary test, and a test in reserve in case of human error in administrating the primary test. We plan to provide our diagnostics initially for use at hospitals, doctors' offices, and clinics. Once production ramps up, we will offer testing kits and meters to patients for testing at-home.